Benzinga | Aug 6, 2021 11:46AM EDT

Jefferies Downgrades BioCryst Pharmaceuticals to Hold

Jefferies analyst Maury Raycroft downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Buy to Hold.